Introduction:
The global pharmaceutical industry is witnessing a surge in the Emergency Use Authorization (EUA) of vaccines in response to the ongoing COVID-19 pandemic. Vaccine manufacturers and regulatory bodies worldwide are working tirelessly to ensure the safe and effective distribution of vaccines. According to recent data, the global vaccine market is expected to reach $100 billion by 2026.
Top 10 Vaccine Emergency Use Authorization Globally 2026:
1. Pfizer-BioNTech – With a production volume of over 2 billion doses, Pfizer-BioNTech’s COVID-19 vaccine has been at the forefront of the global vaccination efforts. The vaccine has received emergency use authorization in over 90 countries.
2. Moderna – Moderna’s mRNA-based vaccine has shown promising results, with a market share of 20% in the global vaccine market. The company has secured emergency use authorization in more than 50 countries.
3. AstraZeneca – AstraZeneca’s vaccine, developed in collaboration with the University of Oxford, has received emergency use authorization in over 100 countries. The vaccine has a production volume of 3 billion doses.
4. Johnson & Johnson – Johnson & Johnson’s single-dose vaccine has been authorized for emergency use in over 60 countries. The company has ramped up production to meet the global demand, with a market share of 15%.
5. Sinovac – Sinovac’s CoronaVac has been widely used in several countries, with emergency use authorization in Asia, South America, and Africa. The vaccine has a production volume of 1.5 billion doses.
6. Sinopharm – Sinopharm’s BBIBP-CorV vaccine has been authorized for emergency use in over 50 countries. The Chinese vaccine manufacturer has exported 500 million doses globally.
7. Bharat Biotech – Covaxin, developed by Bharat Biotech in India, has received emergency use authorization in several countries. The vaccine has a production volume of 1 billion doses.
8. Sputnik V – Russia’s Sputnik V vaccine has been authorized for emergency use in over 60 countries. The vaccine has shown high efficacy rates and a production volume of 2.5 billion doses.
9. Novavax – Novavax’s protein-based vaccine has been authorized for emergency use in the US, Europe, and other regions. The company has a production volume of 1.8 billion doses.
10. Covovax – Developed by the Serum Institute of India in partnership with Novavax, Covovax has received emergency use authorization in several countries. The vaccine has a production volume of 2 billion doses.
Insights:
The global vaccine market is projected to witness significant growth in the coming years, driven by the increasing demand for COVID-19 vaccines and the development of new vaccines for other infectious diseases. With the emergence of new variants of the virus, vaccine manufacturers will continue to innovate and adapt their products to ensure efficacy. By 2026, the global vaccine market is expected to exceed $100 billion, with key players like Pfizer-BioNTech, Moderna, and AstraZeneca leading the way in vaccine distribution and innovation. As countries strive to achieve herd immunity, collaborations between governments, pharmaceutical companies, and regulatory bodies will play a crucial role in ensuring equitable access to vaccines worldwide.
Related Analysis: View Previous Industry Report
